Disulfiram/copper complex inhibiting NFκB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines

被引：113
作者：
Guo, Xiaoxia [1 ]
Xu, Bing [1 ,2 ]
Pandey, Shuchita [1 ]
Goessl, Elisabeth [1 ]
Brown, James [1 ]
Armesilla, Angel L. [1 ]
Darling, John L. [1 ]
Wang, Weiguang [1 ]
机构：
[1] Wolverhampton Univ, Sch Appl Sci, Res Inst Healthcare Sci, Wolverhampton WV1 1SB, England
[2] So Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
来源：
CANCER LETTERS | 2010年 / 290卷 / 01期
关键词：
NF kappa B; Gemcitabine resistance; Disulfiram; Colorectal cancer; Breast cancer; PANCREATIC-CANCER; LUNG-CANCER; 2'; 2'-DIFLUORODEOXYCYTIDINE GEMCITABINE; DEOXYCYTIDINE KINASE; ANTITUMOR-ACTIVITY; STIMULATING FACTOR; PLUS CAPECITABINE; OXIDATIVE STRESS; TUMOR-CELLS; RESISTANCE;
D O I：
10.1016/j.canlet.2009.09.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Most of the gemcitabine (dFdC) resistant cell lines manifested high NF kappa B activity. The NF kappa B activity can be induced by dFdC and 5-FU exposure. The chemosensitizing effect of disulfiram (DS), an anti-alcoholism drug and NF kappa B inhibitor, and copper (Cu) on the chemoresistant cell lines was examined. The DS/Cu complex significantly enhanced the cytotoxicity of dFdC (resistant cells: 12.2-1085-fold) and completely reversed the dFdC resistance in the resitant cell lines. The dFdC-induced NF kappa B activity was markedly inhibited by DS/Cu complex. The data from this study indicated that DS may be used in clinic to improve the therapeutic effect of dFdC in breast and colon cancer patients. (C) 2009 Published by Elsevier Ireland Ltd.
引用
收藏
页码：104 / 113
页数：10
相关论文
共 57 条
[1]   Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin [J].
Arlt, A ;
Vorndamm, J ;
Breitenbroich, M ;
Fölsch, UR ;
Kalthoff, H ;
Schmidt, WE ;
Schäfer, H .
ONCOGENE, 2001, 20 (07) :859-868
[2]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[3]   Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes [J].
Benekli, Mustafa ;
Yildiz, Ramazan ;
Uner, Aytug ;
Er, Ozlem ;
Yamac, Deniz ;
Alkis, Necati ;
Coskun, Ugur ;
Camci, Celalettin ;
Buyukberber, Suleyman .
ONCOLOGY, 2007, 72 (5-6) :308-313
[4]   Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs [J].
Bergman, AM ;
Giaccone, G ;
van Moorsel, CJA ;
Mauritz, R ;
Noordhuis, P ;
Pinedo, HM ;
Peters, GJ .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (15) :1974-1983
[5]   In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant [J].
Bergman, AM ;
Eijk, PP ;
van Haperen, VWTR ;
Smid, K ;
Veerman, G ;
Hubeek, I ;
van den Ijssel, P ;
Ylstra, B ;
Peters, GJ .
CANCER RESEARCH, 2005, 65 (20) :9510-9516
[6]   Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) [J].
Bergman, AM ;
Pinedo, HM ;
Peters, GJ .
DRUG RESISTANCE UPDATES, 2002, 5 (01) :19-33
[7]  
BODENNER DL, 1986, CANCER RES, V46, P2751
[8]   KINETIC-STUDIES ON 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) WITH PURIFIED HUMAN DEOXYCYTIDINE KINASE AND CYTIDINE DEAMINASE [J].
BOUFFARD, DY ;
LALIBERTE, J ;
MOMPARLER, RL .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (09) :1857-1861
[9]   Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells [J].
Cen, DZ ;
Brayton, D ;
Shahandeh, B ;
Meyskens, FL ;
Farmer, PJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6914-6920
[10]   Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity [J].
Chen, Di ;
Cui, Qiuzhi Cindy ;
Yang, Huanjie ;
Dou, Q. Ping .
CANCER RESEARCH, 2006, 66 (21) :10425-10433
123456